Standard of Care and Interventions
At a Glance
HPCA-associated DYT2 dystonia has no single established medication regimen. Treatment is individualized: oral medicines or botulinum toxin injections may reduce symptoms, while deep brain stimulation may be considered for severe, disabling symptoms after careful evaluation.
Managing HPCA-associated dystonia requires a personalized approach because no two people respond to treatment in exactly the same way. Because the condition is so rare, there is no single established medication regimen; instead, care focuses on reducing symptoms, managing pain, and improving daily function. This page explains the current landscape of treatment, from oral medications to advanced surgical options.
Challenges with Oral Medications
For many types of dystonia, doctors trial oral medications to relax the muscles or adjust brain signaling.
- Limited Evidence: In the very small number of reported HPCA cases, evidence regarding medications is limited and of low certainty. Some literature reports that most patients have had a poor or variable response to common antidystonia drugs [1]. However, individual responses vary.
- Commonly Tried Medications: Doctors may still prescribe individualized trials of medications like trihexyphenidyl, baclofen, or levodopa [2][3]. A trial may be useful to target specific goals like better sleep, pain relief, or reduced spasms, even if it does not cure the dystonia [3].
- Balancing Side Effects: These medications can cause side effects like sleepiness, dry mouth, or mood changes [2]. It is important to work with your doctor to record the intended benefit, the trial duration, and any side effects to determine if the medicine should be continued.
Targeting Specific Muscles with Botulinum Toxin
If the dystonia is severely affecting a specific part of the body—such as the neck or a hand—doctors may use botulinum neurotoxin injections [4].
- How it Works: The toxin is injected directly into overactive muscles to temporarily weaken them and reduce spasms [4].
- Dosing Limits and Risks: Dosing limits depend on the specific toxin preparation, the patient’s age, and the targeted muscles [4]. A specialist must prioritize which muscles to treat to stay within safe limits and minimize risks, which can include temporary weakness, difficulty swallowing (dysphagia), or, rarely, generalized effects.
Deep Brain Stimulation (DBS)
For individuals whose dystonia is severe and disabling despite medication trials, Deep Brain Stimulation (DBS) may be considered [5][6].
What is DBS?
DBS involves surgically placing thin wires (electrodes) into a specific part of the brain called the globus pallidus pars interna (GPi) [6]. These electrodes are connected to a battery-operated device placed under the skin. The device sends electrical pulses to the brain to alter the signals causing the dystonia [7].
Evidence for HPCA Cases
Because HPCA-associated dystonia is so rare, evidence for DBS is based on isolated reports.
- Preliminary Results: One case report of a child with an HPCA mutation noted a 51% reduction in their symptoms, measured by the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) [6].
- Understanding the Limitations: This result comes from a single patient. Benefit can be delayed, variable, or uncertain, and DBS may not improve non-motor symptoms like cognitive or communication difficulties [6].
Risks and Burdens of DBS
DBS is an invasive surgery with material burdens that require careful informed consent. Risks include:
- Bleeding or stroke during surgery, infection, and risks related to anesthesia or seizures.
- Hardware problems (such as broken wires) and the need for future surgeries for battery replacement or revisions.
- A significant time commitment for repeated, frequent programming visits to adjust the stimulation settings.
- Potential stimulation-induced side effects, including worsening of speech or swallowing [7][1].
A multidisciplinary team—including a neurosurgeon, movement disorder specialist, and neuropsychologist—will perform a thorough evaluation to determine if DBS is an appropriate option based on your specific goals and symptom severity [5][8].
Common questions in this guide
Which medicines may be tried for HPCA-associated DYT2 dystonia?
How can botulinum toxin injections help DYT2 dystonia?
When might deep brain stimulation be considered for DYT2 dystonia?
How much does GPi-DBS help people with HPCA-associated dystonia?
What are the main risks and long-term demands of DBS?
Get notified when new evidence is published on Primary dystonia, DYT2 type.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
Childhood-Onset Choreo-Dystonia Due to a Recurrent Novel Homozygous Nonsense HPCA Variant: Case Series and Literature Review.
Magrinelli F, Bhatia KP, Beiraghi Toosi M, et al.
Movement disorders clinical practice 2023; (10(1)):101-108 doi:10.1002/mdc3.13529.
PMID: 36698997 - 2
Medication use in childhood dystonia.
Lumsden DE, Kaminska M, Tomlin S, Lin JP
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2016; (20(4)):625-9.
PMID: 26924167 - 3
Clinical Management of Dystonia in Childhood.
Luc QN, Querubin J
Paediatric drugs 2017; (19(5)):447-461 doi:10.1007/s40272-017-0243-3.
PMID: 28620849 - 4
Childhood dystonias.
Tabbal SD
Current treatment options in neurology 2015; (17(3)):339 doi:10.1007/s11940-015-0339-4.
PMID: 25704239 - 5
Elective and Emergency Deep Brain Stimulation in Refractory Pediatric Monogenetic Movement Disorders Presenting with Dystonia: Current Practice Illustrated by Two Cases.
Garofalo M, Beudel M, Dijk JM, et al.
Neuropediatrics 2023; (54(1)):44-52 doi:10.1055/a-1959-9088.
PMID: 36223877 - 6
Case Report of Pediatric HPCA-Associated Dystonia: Analysis of Ca2+ and K+ Channel Dynamics and Experience With Pallidal Deep Brain Stimulation.
Nou-Fontanet L, Ousingsawat J, Aziz M, et al.
Pediatric neurology 2025; (172()):46-52 doi:10.1016/j.pediatrneurol.2025.07.020.
PMID: 40884872 - 7
Deep Brain Stimulation in KMT2B-Related Dystonia: Case Report and Review of the Literature With Special Emphasis on Dysarthria and Speech.
Abel M, Pfister R, Hussein I, et al.
Frontiers in neurology 2021; (12()):662910 doi:10.3389/fneur.2021.662910.
PMID: 34054706 - 8
Successful Pallidal Stimulation in a Patient with KMT2B-Related Dystonia.
Mun JK, Kim AR, Ahn JH, et al.
Journal of movement disorders 2020; (13(2)):154-158 doi:10.14802/jmd.19087.
PMID: 32241076
This page is for informational purposes only and does not constitute medical advice. A movement-disorder team should help you weigh medication, injections, and deep brain stimulation for your individual goals and risks.